Skip to main content

Table 1 (abstract P20). Outcome measures

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Outcome measures Erenumab 140 mg (ATP)(N=424) Erenumab 70 mg (ATP)(N=421)
MMD
 Baseline MMD, mean (SD) 8.23 (2.43) 8.34 (2.48)
 Change from baseline to Week 52 −4.64 (0.19) −4.22 (0.22)
 Change from Week 24 to Week 52 (ATP) −1.78 (0.19) −1.10 (0.21)
Proportion of patients achieving >=50% reduction from baseline in MMD at Week 52, n/N1 (%) 239/368 (64.9) 225/369 (61.0)
MSMD
 Baseline MSMD, mean (SD) 3.49 (3.49) 3.60 (3.41)
 Change from baseline to Week 52 −2.00 (0.15) −1.75 (0.14)
 Change from Week 24 to Week 52 (ATP) −0.98 (0.13) −0.72 (0.14)
  1. Data are presented as mean (SE) unless specified
  2. ATP active treatment phase, MMD monthly migraine days, MSMD monthly acute migraine-specific medication treatment days, SE standard error, SD standard deviation
  3. N1, number of subjects with non-missing percentage change from baseline; % = n/N1 *100;